Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland

Abstract

This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with ADHD. Subsequently, he was evaluated by a physician in Germany (June 2010) who prescribed CT (Bedrocan®, Bediol®). A Finnish neurologist later confirmed the two prescribed medicines (Bedrocan®, October 2010; Bediol®, May 2011) in the patient’s own country of permanent residence (Finland). During a 5-year period of access, Bedrocan®, which mainly contains Δ9-tetrahydrocannabinol (Δ9-THC), was found to be helpful in alleviating the patient’s ADHD symptoms, in particular poor tolerance to frustration, outbursts of anger, boredom, and problems related to concentration. The second CT medication, Bediol®, which contains both Δ9-THC and the phytocannabinoid cannabidiol, was found to neutralize the excessive dronabinol effects of Bedrocan® as well as zo offer other medical benefits (e.g., improved sleep). In addition to the case report, this paper also offers a brief review of the literature surrounding the medical benefits of CT for AD(H)D, which includes observational studies, clinical case reports, and one randomized clinical experiment. This paper also briefly discusses the endocannabinoid system in relation to ADHD, although more preclinical and clinical research is warranted to establish the optimal levels of cannabinoids, terpenes, and dosing regimens, which vary between different ADHD patients.

Beyond Treatment Versus Enhancement: A Qualitative Study of Pharmacological Neuro-Enhancement Among Dutch and Lithuanian University Students

“…Similarly, blurry boundaries have been found for cannabis, which some of our interviewees used as an “indirect cognitive enhancer” (Franke et al, 2016; Hupli et al, 2016). Medical cannabis is reported to hold therapeutic potential for treatment-resistant ADHD among adults (Hupli, 2018), while “recreational” cannabis remains the most widely used “illegal substance” among young people in Europe (EMCDDA, 2019).…”

Cognitive enhancement with licit and illicit stimulants in the Netherlands and Finland: what is the evidence?

“…Therefore, research in this field needs to consider other drugs used for cognitive enhancement purposes beyond prescription stimulants. For instance, cannabis as a cognitive enhancer among students (Franke et al , 2016) and as a potential pharmacotherapy for ADHD (Hupli, 2018) requires further attention, as cannabis remains the most used illicit drug among young people in the two countries (European Monitoring Centre for Drugs and Drug Addiction, 2019). In addition to cannabis as a cognitive enhancer, so-called psychedelic microdosing (Hupli et al , 2019b) has been identified as an emerging trend among young people in Amsterdam (Nabben et al , 2018), further making the argument that cognitive enhancement takes different forms depending on the context.…”

Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases

“…Reduced expression of CB1Rs was also observed in the prefrontal cortex of SHRs, suggesting potential hypoactivation of the CB1R [ 254 ]. Evidence from case studies also suggests an improvement in ADHD symptoms in response to cannabis and cannabinoids consumption [ 255 , 256 ].…”